Log in to your Inderes Free account to see all free content on this page.

Attana

0.01 SEK

0.00 %

Less than 1K followers

ATANA

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

0.00 %

-12.50 %

-12.50 %

-22.22 %

-30.00 %

-72.00 %

-92.41 %

-99.07 %

-95.45 %

Attana conducts research and development of pharmaceuticals. The company specializes in biological interaction characterization, which is used for analysis in the development of new drugs. The company's patented solutions are used in the study of binding properties and macrostructures in cells, proteins, viruses and bacteria. Operations are primarily in the Nordic region and Europe. The company was founded in 2002 and is headquartered in Stockholm.

Market cap

18.06M SEK

Turnover

24.43K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

13.5.

2026

General meeting '26

29.5.

2026

Interim report Q1'26

All

Press releases

ShowingAll content types

Press release4/30/2024, 9:45 AM

BioInvent evaluating Attana Technology

Press release4/25/2024, 1:43 PM

Attana enters the third year of a five-year service and support contract with a leading health institute in the US

Press release4/1/2024, 9:29 AM

New paper using Attana tecnology to understand how viruses enter human cells

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release3/5/2024, 9:44 AM

Attana: One of US leading health institutes has placed an order for an upgrade of an existing instrument, valued at $150k

Press release2/13/2024, 2:14 PM

New paper using Attana Technology to study structures on surface in Ion Liquids demonstrating the effect of surface charges on interaction properties.

Press release1/23/2024, 12:42 PM

New publication using Attana technology towards environmentally friendly and financially viable methods to create functional materials

Press release12/20/2023, 7:30 AM

New article using Attana's technology from National University of Singapore: Immunity differences in vaccinated individuals according to age, gender, lifestyle and other diseases

Press release12/18/2023, 7:30 AM

Attana: Biosensors to characterize immune response to bacterial diseases

Press release12/5/2023, 10:15 AM

Attana and Linnaeus University have published the first part of the science behind immunity profiles

Press release12/4/2023, 8:56 AM

Attana: Breakthrough order with new customer in the USA

Press release11/23/2023, 7:28 AM

Attana: Strengthened collaboration with European biotech customer who extends their service and support agreement for another 12 months.

Press release11/20/2023, 10:55 AM

A new publication using Attana Technology from National University of Singapore examining the neutralization capacity of human IgG antibodies agsinst different mutations of the SARS-CoV-2

Press release11/15/2023, 1:51 PM

Attana: Robust QCM-Based Sensing and Assay Formats in Commercialized Systems

Press release10/4/2023, 3:03 PM

Attana: Dear shareholders and valuable followers,

Press release9/26/2023, 9:33 AM

New publication that shows the strength of Attana's offering in diagnostics, here applied in veterinary medicine.

Press release9/6/2023, 1:14 PM

New publication from National University of Singapore using Attana Technology to study Immune Response from Tuberculosis Exposed Healthy Individuals

Press release8/28/2023, 3:32 PM

The Swedish Knowledge-Foundation has granted SEK 12 million to a project concerning individual immunity profiles for diagnostics and medical development based on Attana's QCM technology.

Press release5/30/2023, 8:41 AM

Education in advanced Attana cell-based assays and practical hands-on training in maintenance.

Press release5/23/2023, 7:23 AM

Attana prolongs service and support contract with European client

Press release5/23/2023, 6:06 AM

Attanas immunity profiles depicted in the Life Science section of yesterday's Dagens Nyheter

Forum discussions

Attana has signed a 5-year contract in the USA, which will positively impact cash flow during the contract period. Earlier this year, news broke about a collaboration and research agreement with a US university hospital. Smaller news items have also recently emerged regarding new...

4/25/2022, 1:58 PM

by Mikael Kahn

4

Cut your losses quickly is a pretty good saying for companies like these.

12/9/2023, 12:32 PM

by Warren Noutopöytätarjoilu

1

A share issue is incoming. I’m wondering if I should finally realize these -95% losses or continue to fund this sinking ship. Is anyone else still on board?

12/8/2023, 12:14 PM

by III21

1

News Powered by Cision Attana plans to move production of consumables to AroCell Attana can today announce that the company has begun a discussion about moving production of

5/5/2022, 4:47 PM

by PP2020

1

This multibagger seems to have multibagged in the other direction, meaning only 1/20th of the value is left.

12/9/2023, 11:10 AM

by Tunturisusi

0

Got a small pile souring at the bottom of my portfolio and I’m not really that excited to participate in the offering. I have to admit I haven’t followed the company’s activities at all lately.

12/9/2023, 8:13 AM

by ghoul

0

Börskollen Kvartalsrapport för perioden 1 januari - 31 mars 2022 i Attana AB Pressmeddelande i aktien Attana. Kvartalsrapport för perioden 1 januari - 31 mars 2022 i Attana AB. Financial overview (not audited by the company’s auditor): Net sales SEK 3.1 (1.1) million Other operating...

5/6/2022, 6:11 AM

by Tume

0

Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.